Investigational Drug Information for Lixivaptan
✉ Email this page to a colleague
What is the development status for investigational drug Lixivaptan?
Lixivaptan is an investigational drug.
There have been 11 clinical trials for Lixivaptan.
The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2008.
The most common disease conditions in clinical trials are Polycystic Kidney Diseases, Kidney Diseases, and Polycystic Kidney, Autosomal Dominant. The leading clinical trial sponsors are CardioKine Inc., Cardiokine Biopharma, LLC, and Palladio Biosciences.
Summary for Lixivaptan
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 178 |
| WIPO Patent Applications | 111 |
| Japanese Patent Applications | 68 |
| Clinical Trial Progress | Phase 3 (2008-04-01) |
| Vendors | 58 |
Recent Clinical Trials for Lixivaptan
| Title | Sponsor | Phase |
|---|---|---|
| Open-label, Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303 | Palladio Biosciences | Phase 3 |
| Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease | Palladio Biosciences | Phase 3 |
| Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease | Palladio Biosciences | Phase 3 |
Clinical Trial Summary for Lixivaptan
Top disease conditions for Lixivaptan
Top clinical trial sponsors for Lixivaptan
US Patents for Lixivaptan
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
